Vanda Pharmaceuticals (NASDAQ:VNDA) was downgraded by investment analysts at ValuEngine from a “hold” rating to a “sell” rating in a research report issued on Friday, ValuEngine reports.

VNDA has been the subject of several other research reports. Zacks Investment Research downgraded shares of Vanda Pharmaceuticals from a “buy” rating to a “hold” rating and set a $15.00 target price for the company. in a research note on Saturday, October 5th. BidaskClub lowered shares of Vanda Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday. Stifel Nicolaus restated a “hold” rating and issued a $17.00 price objective on shares of Vanda Pharmaceuticals in a research report on Thursday. Finally, Citigroup lowered shares of Vanda Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $19.00 price objective for the company. in a research report on Thursday. Three investment analysts have rated the stock with a sell rating, six have assigned a hold rating and two have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $26.71.

Shares of VNDA traded up $0.21 during trading hours on Friday, hitting $14.74. The company’s stock had a trading volume of 787,900 shares, compared to its average volume of 762,937. The company has a market cap of $719.20 million, a price-to-earnings ratio of 30.71 and a beta of 0.29. The business has a 50 day simple moving average of $13.51 and a two-hundred day simple moving average of $14.36. Vanda Pharmaceuticals has a 52-week low of $11.83 and a 52-week high of $33.44.

Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $1.84 earnings per share for the quarter, topping the consensus estimate of $0.07 by $1.77. The firm had revenue of $59.49 million during the quarter, compared to the consensus estimate of $58.33 million. Vanda Pharmaceuticals had a net margin of 13.61% and a return on equity of 10.23%. The company’s revenue was up 21.1% on a year-over-year basis. During the same quarter last year, the company earned $0.13 earnings per share. As a group, sell-side analysts anticipate that Vanda Pharmaceuticals will post 0.3 EPS for the current year.

In other news, SVP Timothy Williams sold 2,575 shares of the firm’s stock in a transaction that occurred on Wednesday, August 14th. The shares were sold at an average price of $14.69, for a total value of $37,826.75. Following the completion of the transaction, the senior vice president now directly owns 57,425 shares in the company, valued at $843,573.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Richard W. Dugan sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $14.85, for a total transaction of $222,750.00. Following the completion of the transaction, the director now owns 50,770 shares of the company’s stock, valued at $753,934.50. The disclosure for this sale can be found here. 8.20% of the stock is currently owned by company insiders.

Several hedge funds have recently added to or reduced their stakes in VNDA. North Star Investment Management Corp. bought a new position in shares of Vanda Pharmaceuticals in the third quarter valued at approximately $66,000. Meeder Asset Management Inc. boosted its position in shares of Vanda Pharmaceuticals by 1,638.3% in the third quarter. Meeder Asset Management Inc. now owns 5,215 shares of the biopharmaceutical company’s stock valued at $69,000 after acquiring an additional 4,915 shares during the period. Clarus Wealth Advisors bought a new position in shares of Vanda Pharmaceuticals in the third quarter valued at approximately $133,000. Pacer Advisors Inc. bought a new stake in Vanda Pharmaceuticals during the second quarter valued at approximately $138,000. Finally, Zebra Capital Management LLC bought a new stake in Vanda Pharmaceuticals during the second quarter valued at approximately $170,000.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia.

Read More: Dividend Achievers

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.